BioCentury
ARTICLE | Product Development

Latest cut of data shows AZ vaccine has higher rates of rare thrombosis 

Regulators left to tease out why rates higher in lone vaccine

April 7, 2021 1:25 AM UTC

The most recent set of COVID-19 vaccine adverse events in Europe show a higher frequency of several rare types of thromboembolic events in individuals given AstraZeneca’s vaccine compared with others approved in the U.K. and EU.

As an EMA safety committee readies to give an updated recommendation on use of the vaccine, the regulator may be weighing whether the issue is specific to the one vaccine and, if so, why. ...

BCIQ Company Profiles

AstraZeneca plc